| Basics |
Amgen Inc.
Amgen Inc is a U.S. based biotechnology company, with historical expertise in renal disease and cancer supportive care products. The firm discovers, develops, manufactures and delivers human therapeutics.
|
| IPO Date: |
January 2, 1990 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$172.98B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.42 | 0.99%
|
| Avg Daily Range (30 D): |
$4.35 | 1.35%
|
| Avg Daily Range (90 D): |
$3.44 | 1.14%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
4.78M |
| Avg Daily Volume (30 D): |
2.17M |
| Avg Daily Volume (90 D): |
1.83M |
| Trade Size |
| Avg Trade Size (Sh.): |
131 |
| Avg Trade Size (Sh.) (30 D): |
29 |
| Avg Trade Size (Sh.) (90 D): |
32 |
| Institutional Trades |
| Total Inst.Trades: |
114,281 |
| Avg Inst. Trade: |
$6.36M |
| Avg Inst. Trade (30 D): |
$36.1M |
| Avg Inst. Trade (90 D): |
$34.58M |
| Avg Inst. Trade Volume: |
.05M |
| Avg Inst. Trades (Per Day): |
20 |
| Market Closing Trades |
| Avg Closing Trade: |
$65.64M |
| Avg Closing Trade (30 D): |
$176.74M |
| Avg Closing Trade (90 D): |
$148.97M |
| Avg Closing Volume: |
388.54K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
|
$5.98
|
$2.66
|
|
Diluted EPS
|
|
$5.93
|
$2.65
|
|
Revenue
|
$
|
$ 9.56B
|
$ 9.18B
|
|
Gross Profit
|
$
|
$ 6.48B
|
$ 6.17B
|
|
Net Income / Loss
|
$
|
$ 3.22B
|
$ 1.43B
|
|
Operating Income / Loss
|
$
|
$ 2.53B
|
$ 2.66B
|
|
Cost of Revenue
|
$
|
$ 3.08B
|
$ 3.01B
|
|
Net Cash Flow
|
$
|
$ 1.42B
|
$ -782M
|
|
PE Ratio
|
|
|
|
|
|
|
